RE:RE:RE:RE:RE:2018 AGM Uplist to Another Exchange"A good company is a good company no matter what exchange it is on. I am certain that if Gilles makes some big deals with well established bio tech compaines the exposure would be fantastic and the share price will go up."
Good companies don't sell-out everything they have at an early stage. CZO is a good company. Unlike other biotech companies that don't have a profitable base business that can finance a pipeline internally CZO has a profitable base business. It has been able to keep 100% control over its pipeline and has the cash to get to the next strategic and value transforming events. This is what many on this message board hate about CZO. It hasn't had to sell out early in a Mickey Mouse deal. If CZO wants to continue to advance some of its programs internally, into the future, it is going to need access to significant capital and the US is the center of the biotech universe. Canada doesn't have the scale needed for what may come next for CZO. Avalyn, for instance, raise C$80 million going into its Phase I fibrosis trial. Do you think the Canadian biotech market is the best place to raise tens-of-million for a biotech? A 1000L PGX may also need $40 million for the immune booster. What if the avenanthramide results are very compelling and CZO wants to advance it further in the clinic? CZO is a potential monster and needs access to monster capital if it wants to maximize shareholder value and not sell everything off early.